The estimated Net Worth of Matthew S Crawford is at least $4.17 Milhão dollars as of 20 June 2018. Matthew Crawford owns over 363,500 units of Apollo Endosurgery Inc stock worth over $4,172,150 and over the last 8 years Matthew sold APEN stock worth over $0.
Matthew has made over 4 trades of the Apollo Endosurgery Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Matthew bought 363,500 units of APEN stock worth $1,999,250 on 20 June 2018.
The largest trade Matthew's ever made was buying 1,136,363 units of Apollo Endosurgery Inc stock on 25 July 2017 worth over $6,249,997. On average, Matthew trades about 209,988 units every 41 days since 2016. As of 20 June 2018 Matthew still owns at least 417,215 units of Apollo Endosurgery Inc stock.
You can see the complete history of Matthew Crawford stock trades at the bottom of the page.
Matthew's mailing address filed with the SEC is 3600 N Capital of Texas Hwy b180, Austin, TX 78746, USA.
Over the last 12 years, insiders at Apollo Endosurgery Inc have traded over $3,882,241 worth of Apollo Endosurgery Inc stock and bought 10,717,094 units worth $45,588,363 . The most active insiders traders include Holdings A/S Novo, Neil Gagnon, eR Kent Jr Mc Gaughy. On average, Apollo Endosurgery Inc executives and independent directors trade stock every 41 days with the average trade being worth of $2,726,880. The most recent stock trade was executed by Jeffrey G. Black on 25 February 2022, trading 40,000 units of APEN stock currently worth $229,200.
Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.
Apollo Endosurgery Inc executives and other stock owners filed with the SEC include: